Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Design and validation of a new instrument to assess fear of falling in Parkinson's disease.

Terroba-Chambi C, Bruno V, Millar-Vernetti P, Bruce D, Brockman S, Merello M, Starkstein S.

Mov Disord. 2019 Oct;34(10):1496-1504. doi: 10.1002/mds.27820. Epub 2019 Aug 23.

PMID:
31442364
2.

Treatment of Post-Stroke Depression.

Starkstein SE, Hayhow BD.

Curr Treat Options Neurol. 2019 Jun 25;21(7):31. doi: 10.1007/s11940-019-0570-5. Review.

PMID:
31236751
3.

Anosognosia Is Associated With Greater Caregiver Burden and Poorer Executive Function in Huntington Disease.

Wibawa P, Zombor R, Dragovic M, Hayhow B, Lee J, Panegyres PK, Rock D, Starkstein SE.

J Geriatr Psychiatry Neurol. 2020 Jan;33(1):52-58. doi: 10.1177/0891988719856697. Epub 2019 Jun 18.

PMID:
31213121
4.

Apathy in Dementia: Time to StandUp.

Starkstein S, Hayhow B.

Am J Geriatr Psychiatry. 2019 Apr;27(4):406-407. doi: 10.1016/j.jagp.2018.12.035. Epub 2019 Jan 9. No abstract available.

PMID:
30765290
5.

Modified Mindfulness-Based Cognitive Therapy for Depressive Symptoms in Parkinson's Disease: a Pilot Trial.

Rodgers SH, Schütze R, Gasson N, Anderson RA, Kane RT, Starkstein S, Morgan-Lowes K, Egan SJ.

Behav Cogn Psychother. 2019 Jul;47(4):446-461. doi: 10.1017/S135246581800070X. Epub 2019 Jan 18.

PMID:
30654854
6.

Discerning depressive symptoms in patients with obstructive sleep apnea: the effect of continuous positive airway pressure therapy on Hamilton Depression Rating Scale symptoms.

Bucks RS, Nanthakumar S, Starkstein SS, Hillman DR, James A, McArdle N, Hatch K, Skinner TC.

Sleep. 2018 Dec 1;41(12). doi: 10.1093/sleep/zsy178.

PMID:
30203079
7.

Clinical risk factors for depressive syndrome in Type 2 diabetes: the Fremantle Diabetes Study.

Bruce DG, Davis WA, Starkstein SE, Davis TME.

Diabet Med. 2018 Jul;35(7):903-910. doi: 10.1111/dme.13631. Epub 2018 May 2.

PMID:
29608787
8.

Hippocampal atrophy, asymmetry, and cognition in type 2 diabetes mellitus.

Milne NT, Bucks RS, Davis WA, Davis TME, Pierson R, Starkstein SE, Bruce DG.

Brain Behav. 2017 Dec 22;8(1):e00741. doi: 10.1002/brb3.741. eCollection 2018 Jan.

9.

The utility of the Diabetes Anxiety Depression Scale in Type 2 diabetes mellitus: The Fremantle Diabetes Study Phase II.

Davis WA, Bruce DG, Dragovic M, Davis TME, Starkstein SE.

PLoS One. 2018 Mar 15;13(3):e0194417. doi: 10.1371/journal.pone.0194417. eCollection 2018.

10.

The neuroimaging basis of apathy: Empirical findings and conceptual challenges.

Starkstein SE, Brockman S.

Neuropsychologia. 2018 Sep;118(Pt B):48-53. doi: 10.1016/j.neuropsychologia.2018.01.042. Epub 2018 Feb 2. Review.

PMID:
29410070
11.

Management of Depression in Parkinson's Disease: A Systematic Review.

Starkstein SE, Brockman S.

Mov Disord Clin Pract. 2017 Jun 1;4(4):470-477. doi: 10.1002/mdc3.12507. eCollection 2017 Jul-Aug. Review.

12.

Neuroimaging and its Relevance to Understanding Pathways Linking Diabetes and Cognitive Dysfunction.

Moran C, Beare R, Phan T, Starkstein S, Bruce D, Romina M, Srikanth V.

J Alzheimers Dis. 2017;59(2):405-419. doi: 10.3233/JAD-161166. Review.

PMID:
28527209
13.

Depression symptoms are persistent in Type 2 diabetes: risk factors and outcomes of 5-year depression trajectories using latent class growth analysis.

Whitworth SR, Bruce DG, Starkstein SE, Davis WA, Davis TME, Skinner TC, Bucks RS.

Diabet Med. 2017 Aug;34(8):1108-1115. doi: 10.1111/dme.13372. Epub 2017 May 16.

PMID:
28453875
14.

The Structured Interview for Insight and Judgment in Dementia: Development and validation of a new instrument to assess awareness in patients with dementia.

Parrao T, Brockman S, Bucks RS, Bruce DG, Davis WA, Hatch KK, Leavy TL, Axten CA, Starkstein SE.

Alzheimers Dement (Amst). 2016 Dec 26;7:24-32. doi: 10.1016/j.dadm.2016.12.012. eCollection 2017.

15.

Assessment of the Depression, Anxiety, and Stress Scale (DASS-21) in untreated obstructive sleep apnea (OSA).

Nanthakumar S, Bucks RS, Skinner TC, Starkstein S, Hillman D, James A, Hunter M.

Psychol Assess. 2017 Oct;29(10):1201-1209. doi: 10.1037/pas0000401. Epub 2016 Dec 12.

16.

Lifetime depression and anxiety increase prevalent psychological symptoms and worsen glycemic control in type 2 diabetes: The Fremantle Diabetes Study Phase II.

Whitworth SR, Bruce DG, Starkstein SE, Davis WA, Davis TM, Bucks RS.

Diabetes Res Clin Pract. 2016 Dec;122:190-197. doi: 10.1016/j.diabres.2016.10.023. Epub 2016 Nov 9.

PMID:
27865961
17.

Dementia onset, incidence and risk in type 2 diabetes: a matched cohort study with the Fremantle Diabetes Study Phase I.

Davis WA, Zilkens RR, Starkstein SE, Davis TM, Bruce DG.

Diabetologia. 2017 Jan;60(1):89-97. Epub 2016 Oct 7.

18.

Amygdala Volumetric Change Following Psychotherapy for Posttraumatic Stress Disorder.

Laugharne J, Kullack C, Lee CW, McGuire T, Brockman S, Drummond PD, Starkstein S.

J Neuropsychiatry Clin Neurosci. 2016 Fall;28(4):312-318. doi: 10.1176/appi.neuropsych.16010006. Epub 2016 Jun 3.

PMID:
27255857
19.

Comorbid Anxiety and Depression and Their Impact on Cardiovascular Disease in Type 2 Diabetes: The Fremantle Diabetes Study Phase II.

Bruce DG, Davis WA, Dragovic M, Davis TM, Starkstein SE.

Depress Anxiety. 2016 Oct;33(10):960-966. doi: 10.1002/da.22523. Epub 2016 May 10.

PMID:
27164424
20.

A Randomized, Placebo-Controlled, Double-Blind Efficacy Study of Nefiracetam to Treat Poststroke Apathy.

Starkstein SE, Brockman S, Hatch KK, Bruce DG, Almeida OP, Davis WA, Robinson RG.

J Stroke Cerebrovasc Dis. 2016 May;25(5):1119-1127. doi: 10.1016/j.jstrokecerebrovasdis.2016.01.032. Epub 2016 Feb 22.

PMID:
26915605
21.

Modeling anxiety in Parkinson's disease.

Broen MP, Köhler S, Moonen AJ, Kuijf ML, Dujardin K, Marsh L, Richard IH, Starkstein SE, Martinez-Martin P, Leentjens AF.

Mov Disord. 2016 Mar;31(3):310-6. doi: 10.1002/mds.26461. Epub 2015 Dec 21.

PMID:
26685935
22.

Lifetime depression history and depression risk in type 2 diabetes: A case-control study.

Bruce DG, Davis WA, Hunter ML, Peters KE, Davis TM, Starkstein SE.

J Diabetes Complications. 2016 Jan-Feb;30(1):38-42. doi: 10.1016/j.jdiacomp.2015.10.010. Epub 2015 Oct 21.

PMID:
26604164
23.

The 'Preliminary Discourse' to Methodical Nosology, by François Boissier de Sauvages (1772).

Starkstein SE, Berrios GE.

Hist Psychiatry. 2015 Dec;26(4):477-91. doi: 10.1177/0957154X15602361.

PMID:
26574063
24.

Drowning hazard with deep brain stimulation: case report.

Bangash OK, Thorburn M, Garcia-Vega J, Walters S, Stell R, Starkstein SE, Lind CR.

J Neurosurg. 2016 May;124(5):1513-6. doi: 10.3171/2015.5.JNS15589. Epub 2015 Nov 13.

PMID:
26566200
25.

Cognitive Behaviour Therapy for Depression and Anxiety in Parkinson's Disease.

Egan SJ, Laidlaw K, Starkstein S.

J Parkinsons Dis. 2015;5(3):443-51. doi: 10.3233/JPD-150542. Review.

26.

Phenomenology of Depression in Alzheimer's Disease.

Novais F, Starkstein S.

J Alzheimers Dis. 2015;47(4):845-55. doi: 10.3233/JAD-148004. Review.

PMID:
26401763
27.

The interactive effects of type 2 diabetes mellitus and schizophrenia on all-cause mortality: The Fremantle Diabetes Study.

Davis WA, Starkstein SE, Bruce DG, Davis TM.

J Diabetes Complications. 2015 Nov-Dec;29(8):1320-2. doi: 10.1016/j.jdiacomp.2015.08.019. Epub 2015 Aug 28.

PMID:
26387807
28.

Risk of suicide in Australian adults with diabetes: the Fremantle Diabetes Study.

Davis WA, Starkstein SE, Bruce DG, Davis TM.

Intern Med J. 2015 Sep;45(9):976-80. doi: 10.1111/imj.12853.

PMID:
26332624
29.

High rates of parkinsonism in adults with autism.

Starkstein S, Gellar S, Parlier M, Payne L, Piven J.

J Neurodev Disord. 2015;7(1):29. doi: 10.1186/s11689-015-9125-6. Epub 2015 Aug 30.

30.

The impact of emotional distress on motor blocks and festination in Parkinson's disease.

Starkstein S, Dragovic M, Brockman S, Wilson M, Bruno V, Merello M.

J Neuropsychiatry Clin Neurosci. 2015;27(2):121-6. doi: 10.1176/appi.neuropsych.13030053.

PMID:
25923851
31.

Prevalence of depression and its associations with cardio-metabolic control in Aboriginal and Anglo-Celt patients with type 2 diabetes: the Fremantle Diabetes Study Phase II.

Davis TM, Hunt K, Bruce DG, Starkstein S, Skinner T, McAullay D, Davis WA.

Diabetes Res Clin Pract. 2015 Mar;107(3):384-91. doi: 10.1016/j.diabres.2014.12.014. Epub 2015 Jan 21.

PMID:
25656760
32.

Is the Parkinson Anxiety Scale comparable across raters?

Forjaz MJ, Ayala A, Martinez-Martin P, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Leentjens AF.

Mov Disord. 2015 Apr;30(4):545-51. doi: 10.1002/mds.26111. Epub 2014 Dec 27.

PMID:
25546697
33.

Factor analysis of the Hamilton Depression Rating Scale in Parkinson's disease.

Broen MP, Moonen AJ, Kuijf ML, Dujardin K, Marsh L, Richard IH, Starkstein SE, Martinez-Martin P, Leentjens AF.

Parkinsonism Relat Disord. 2015 Feb;21(2):142-6. doi: 10.1016/j.parkreldis.2014.11.016. Epub 2014 Nov 29.

PMID:
25523963
34.

Anosognosia in Alzheimer's disease: diagnosis, frequency, mechanism and clinical correlates.

Starkstein SE.

Cortex. 2014 Dec;61:64-73. doi: 10.1016/j.cortex.2014.07.019. Review.

PMID:
25481465
35.

Apathy in older patients with type 2 diabetes.

Bruce DG, Nelson ME, Mace JL, Davis WA, Davis TM, Starkstein SE.

Am J Geriatr Psychiatry. 2015 Jun;23(6):615-21. doi: 10.1016/j.jagp.2014.09.010. Epub 2014 Oct 2.

36.

Diagnostic criteria for depression in type 2 diabetes: a data-driven approach.

Starkstein SE, Davis WA, Dragovic M, Cetrullo V, Davis TM, Bruce DG.

PLoS One. 2014 Nov 12;9(11):e112049. doi: 10.1371/journal.pone.0112049. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0122324.

37.

The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale.

Leentjens AF, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin P.

Mov Disord. 2014 Jul;29(8):1035-43. doi: 10.1002/mds.25919. Epub 2014 May 23.

38.

Mid-life predictors of cognitive impairment and dementia in type 2 diabetes mellitus: the Fremantle Diabetes Study.

Bruce DG, Davis WA, Starkstein SE, Davis TM.

J Alzheimers Dis. 2014;42 Suppl 3:S63-70. doi: 10.3233/JAD-132654.

PMID:
24840567
39.

Apathy following traumatic brain injury.

Starkstein SE, Pahissa J.

Psychiatr Clin North Am. 2014 Mar;37(1):103-12. doi: 10.1016/j.psc.2013.10.002. Epub 2014 Jan 10. Review.

PMID:
24529426
40.

Clinical impact of the temporal relationship between depression and type 2 diabetes: the Fremantle diabetes study phase II.

Bruce DG, Davis WA, Cetrullo V, Starkstein SE, Davis TM.

PLoS One. 2013 Dec 4;8(12):e81254. doi: 10.1371/journal.pone.0081254. eCollection 2013.

41.

Imaging apathy in Alzheimer's disease.

Starkstein SE.

Int Psychogeriatr. 2014 Feb;26(2):193. doi: 10.1017/S1041610213002214. Epub 2013 Dec 2. No abstract available.

PMID:
24290158
42.

Anxiety has specific syndromal profiles in Parkinson disease: a data-driven approach.

Starkstein SE, Dragovic M, Dujardin K, Marsh L, Martinez-Martin P, Pontone GM, Richard IH, Weintraub D, Leentjens AF.

Am J Geriatr Psychiatry. 2014 Dec;22(12):1410-7. doi: 10.1016/j.jagp.2013.09.006. Epub 2013 Nov 5.

PMID:
24200594
43.

Clinical issues in the treatment of anxiety and depression in older adults with Parkinson's disease.

Pachana NA, Egan SJ, Laidlaw K, Dissanayaka N, Byrne GJ, Brockman S, Marsh R, Starkstein S.

Mov Disord. 2013 Dec;28(14):1930-4. doi: 10.1002/mds.25689. Epub 2013 Oct 9. Review.

PMID:
24123116
44.

Modeling depression in Parkinson disease: disease-specific and nonspecific risk factors.

Leentjens AF, Moonen AJ, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Köhler S.

Neurology. 2013 Sep 17;81(12):1036-43. doi: 10.1212/WNL.0b013e3182a4a503. Epub 2013 Aug 14.

45.

Rasch analysis of anxiety scales in Parkinson's disease.

Forjaz MJ, Martinez-Martin P, Dujardin K, Marsh L, Richard IH, Starkstein SE, Leentjens AF.

J Psychosom Res. 2013 May;74(5):414-9. doi: 10.1016/j.jpsychores.2013.02.009. Epub 2013 Mar 19.

PMID:
23597329
46.

Designing a new scale to measure anxiety symptoms in Parkinson's disease: item selection based on canonical correlation analysis.

Martinez-Martin P, Rojo-Abuin JM, Dujardin K, Pontone GM, Weintraub D, Forjaz MJ, Starkstein S, Leentjens AF.

Eur J Neurol. 2013 Aug;20(8):1198-203. doi: 10.1111/ene.12160. Epub 2013 Apr 14.

PMID:
23581431
47.

Psychiatric syndromes in Parkinson's disease.

Starkstein SE, Brockman S, Hayhow BD.

Curr Opin Psychiatry. 2012 Nov;25(6):468-72. doi: 10.1097/YCO.0b013e3283577ed1. Review.

48.

Anxiety and motor fluctuations in Parkinson's disease: a cross-sectional observational study.

Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE.

Parkinsonism Relat Disord. 2012 Dec;18(10):1084-8. doi: 10.1016/j.parkreldis.2012.06.007. Epub 2012 Jul 6.

PMID:
22771284
49.

Neurological and psychiatric aspects of emotion.

Starkstein SE, Tranel D.

Handb Clin Neurol. 2012;106:53-74. doi: 10.1016/B978-0-444-52002-9.00004-8. Review.

PMID:
22608615
50.

Neuropsychiatry of Parkinson's disease.

Teixeira AL, Fontenelle LF, Lauterbach EC, Starkstein S.

Parkinsons Dis. 2012;2012:908943. doi: 10.1155/2012/908943. Epub 2012 Apr 17. No abstract available.

Supplemental Content

Loading ...
Support Center